Introgen Therapeutics Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Introgen Therapeutics

INGN 6.800

+1.9%

Dec 26 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Ian@SI	12/28/2006 8:13:13 PM
	Read Replies (1) of 802

Z. and B., You guys missed one. ;^) 11:05AM Introgen announces conference call; phase 3 trial analysis plans and new clinical data to be discussed (INGN) 4.66 +0.14 : Co confirmed it will host a conference call to update its regulatory and clinical developments including its plans to begin the analyses of Phase 3 ADVEXIN trials. Management will comment upon the agreement between the co and the FDA for the statistical analysis plan of ADVEXIN phase 3 clinical trials to support product licensure for recurrent head and neck cancers. In addition, activities in the co's program to register ADVEXIN with the European Medicines Evaluation Agency will be reviewed. Also to be highlighted are the recently reported ADVEXIN clinical biomarker data which has provided high statistical significance for both increased survival and tumor response in p53 biomarker-defined patients. Mgmt will discuss financial and corporate developments and report on successful steps to strengthen its capital resources through recent sales of $30 mln in common stock. The call will be held today, Dec 28, 2006, at 4:30 p.m. Eastern Time.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next